drugset / Trial / NCT00878722
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
An open-label, non-randomized, multi-centre, Phase I/II trial to assess the efficacy and safety of 2 schedules of PXD101 in combination with idarubicin in patients with AML not suitable for standard intensive therapy.
Timeline
- Start
- 2007-08
- Primary completion
- 2009-05
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belinostat | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | — | — |